Pipeline Powerhouse | Explore JNJ's robust pipeline, featuring potential blockbusters like Nipocalimab and TAR-200, each with projected peak sales exceeding $5 billion annually |
Market Dynamics | Delve into JNJ's strategic positioning in oncology and immunology, balancing innovation with challenges like Stelara's patent expiration in Europe |
Financial Outlook | JNJ narrows 2024 guidance, projecting sales between $88.0-$88.4 billion and adjusted EPS of $10.57-$10.72, reflecting confidence amid market uncertainties |
Analyst Perspectives | Price targets range from $175 to $215, with Cantor Fitzgerald bullish at $215 and RBC Capital Markets more conservative at $175, highlighting varied outlooks |
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Metrics to compare | JNJ | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipJNJPeersSector | |
---|---|---|---|---|
P/E Ratio | 23.6x | 20.2x | −0.6x | |
PEG Ratio | 0.11 | 0.04 | 0.00 | |
Price/Book | 5.4x | 6.0x | 2.6x | |
Price / LTM Sales | 4.5x | 3.5x | 3.2x | |
Upside (Analyst Target) | 6.1% | 77.0% | 48.5% | |
Fair Value Upside | Unlock | 8.9% | 7.8% | Unlock |